No services found
No Products found
100µg
IgG1
ProteoGenix
COVID-19 products
Monoclonal Antibody
The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the most important target for the design of novel therapies for COVID-19. The development of antibodies that can target this specific area can be done in vivo, which is a time-consuming in vitro process or which can take advantage of the flexibility of visualization technologies such as pH age visualization. Anti-CoV-RBD antibody was developed by pHa to visualize the extensive library of COVID-19 (LiAb-SFCOVID-19 ™) antibodies against SARS-CoV-2 RBD. Whereas generation of antibodies based on pH age does not require animal immunization or the use of immunogenic antigens, only small RBD proteins are used to isolate specific RBD ligands from the LiAb-SFCOVID-19 TM library. Furthermore, since the library is composed of immune libraries from COVID-19 patients, it possesses the largest and most important biological antibodies with important neutralizing activities. Therefore, this specific antibody is a fully human immunoglobulin in IgG format. The ELISA (Enzyme-linked immunosorbent assay) test was used to test and verify its affinity for recombinantly expressed RBD. In addition, the neutralizing activity was tested by the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), which is designed to rapidly assess the neutralization potential of new antibodies without using natural viral particles. Finally, IgG antibodies are expressed in the XtenCHO ™ high throughput mammalian transient system, exhibit very stable stability and consistently produce high yields.
Anti-RBD-4 antibody (Casirivimab), on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Publication
Fiedler, S., Devenish, S.R.A., Morgunov, A.S. et al. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. Sci Rep 12, 19791 (2022). https://doi.org/10.1038/s41598-022-22214-z
Reviews
Toshi – March 11, 2022
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants(9.44 ng/mL for the wild type, 5.23 ng/mL for Alpha, >500 ng/mL for Gamma, 1.94 ng/mL for Delta).
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? * WB ELISA Sandwich ELISA IF IHC IP FC other
Did it work in your application? * Yes No
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Related products
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.